CLDX Celldex Therapeutics Inc.
9,806
$39.92
$1.14
(2.78%)
| Watchers | 9,806 |
| 52-Wk Low | $22.11 |
| 52-Wk High | $53.18 |
| Market Cap | $2.71B |
| Volume | 504,888.00 |
| 52-Wk High | $53.18 |
| 52-Wk Low | $22.11 |
Unveiling 4 Analyst Insights On Celldex TherapeuticsBenzinga • 4 days ago
Latest Ratings for CLDX
DateFirmActionFromTo Sep 2021JefferiesInitiates Coverage OnBuy Sep 2021HC Wainwright & Co.MaintainsBuy Sep 2021SVB LeerinkInitiates Coverage OnOutperform
View More...
Share to Feed
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the firm, MarketBeat.com...
This price move could indicate a change in the trend, and may be a buy signal for investors...
Celldex Therapeutics, Inc. (NASDAQ:CLDX Get Free Report) was the target of a large decline in short interest in the month of February. As of February 29th, there was short interest totalling...
GSA Capital Partners LLP lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX Free Report) by 192.0% in the 3rd quarter, according to its most recent Form 13F filing with the...
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global...
Related Stocks: FRA:TCE2...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Celldex Therapeutics, Inc. (CLDX), where a total of 9,083 contracts have traded so far...
This is a signal that CLDX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an...